“At Panion we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects.”
Anja Holm, CEO
Developing animal health
Our treatment process
Normal synaptic communication
Normal glutamate release
Excessive glutamate release
Excessive synaptic communication
Preparing a gene vector
Vector enters brain cell
Increased expression of NPY and Y2
NPY and Y2 decreasing excessive glutamate release
Back to normal synaptic communication
Panion Animal Health AB was founded in July 2015 as a wholly owned subsidiary of CombiGene AB and with the purpose to develop and commercialize the canine (dog) application of CombiGene AB’s technology. In 2016, Panion was distributed to CombiGene AB’s shareholders, and it became a registered Swedish public company. The Panion share has been listed on Spotlight Stock Market since 05/07/2017 under the ticker PANION and is traded through banks and stockbrokers.
We want to improve the quality of life for animals with chronic diseases and we are convinced that gene therapy holds the promise for the future. To move from science to business requires knowledge, competence, determination, and financing. Since November 2016, the board and management have developed the business plan, gained access to relevant preclinical and clinical data, finalised a safety study in dogs and held meetings with competent authorities for veterinary medicines in EU and USA.
The objective for Panion’s operation is to combine gene therapy with the scientific understanding of chronic diseases to develop effective treatments for animals.
Management & Board
Anja E. H. Holm
Chief Executive Officer
Carlos N. Velez
Director Business Development
Chief Financial Officer
Chairman of the board
Lars Friis Mikkelsen